OncLive® On Air S9 Ep23: Usmani Highlights the Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
Sep 4, 2023
Dr. Usmani discusses the use of bispecific antibodies in treating relapsed/refractory multiple myeloma, emphasizing their integration into current management strategies. Topics include adverse effects, supportive care, patient selection, dosing considerations, toxicity management, and ongoing research for improved treatment outcomes.
Chapters
Transcript
Episode notes
1 2 3 4 5
Introduction
00:00 • 2min
Bi-specific Antibodies in Treating Multiple Myeloma
01:57 • 4min
Exploring Sequencing and Resistance Mechanisms in BCMA-Directed Therapies
06:14 • 2min
Patient Selection and Dosing Considerations for Bispecific Antibodies in Multiple Myeloma
08:40 • 2min
Toxicity Management and Ongoing Studies in Bispecific Antibody Treatment
10:58 • 4min